BSE: 524606
BERYL DRUGS LTD.
Manufactures pharmaceutical products including IV fluids, oral solid doses, and PP Bottle and FFS (Form Fill Seal) products, sold to distributors and end-markets. Distribution for PP Bottle and FFS products in Maharashtra, Gujarat and exports was handed to Aminova Infusions Pvt Ltd under a ₹5 crore related-party arrangement running from January 2026, representing about 13.30% of annual consolidated turnover. Revenue in FY26 was ₹18.82 crore and net profit was ₹0.4248 crore, with the year hit by a manufacturing stop order from the Food and Drugs Administration, Madhya Pradesh in January 2025 that suspended the Blow Fill Seal (BFS) section until November 2025, contributing to a revenue decline of roughly 14.4% versus FY25. Materials account for 55.8% of revenue, employee cost 13.4%, other opex 24.4%, depreciation 7.9%, and capex was 20.3% of revenue, pointing to an asset-light manufacturing model. Listed on BSE with 50.71 lakh shares outstanding and not classified as a Large Corporate under SEBI thresholds. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. PP Bottle products, FFS (Form Fill Seal) products, IV fluids, Oral Solid Doses. Small, asset-light pharmaceutical manufacturer.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 15 | 27 | 27 | 21 | 19 |
| EBITDA (ex other income) | 0 | 2 | 2 | 1 | 2 |
| margin % | 2.8 | 7.2 | 8.5 | 5.8 | 10.3 |
| Owners' profit | (1) | 1 | 1 | 1 | 0 |
| EPS, as reported (₹) | (1.30) | 1.52 | 1.52 | 1.14 | 0.30 |
| ROE % · ROCE % | (9.0) · (4.9) | 9.5 · 12.5 | 8.6 · 12.6 | 6.1 · 12.0 | 4.3 · 8.9 |
| Debt / equity (x) | 0.73 | 0.56 | 0.57 | 0.43 | 0.24 |
| Cash from operations | (0) | 2 | 1 | 3 | 4 |
| Capex | (0) | (2) | (1) | (2) | (4) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 6 | 5 | 4 | 5 | 5 | 4 | 5 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 1 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | (0) | 1 |
| EPS (₹) | 0.73 | 0.01 | 0.10 | 0.30 | 0.04 | 0.02 | (0.33) | 1.11 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.8 | 30.8 | 79 of 158 | 50% |
| P/B | 1.3 | 3.1 | 36 of 163 | 78% |
| ROCE | 5.6 | 10.8 | 121 of 183 | 34% |
| ROE | 4.3 | 9.8 | 120 of 166 | 28% |
| Debt / Equity | 0.2 | 0.2 | 102 of 166 | 38% |
| EBITDA margin | 26.1 | 17.5 | 47 of 165 | 72% |
| Revenue growth | 29.1 | 16.3 | 50 of 161 | 69% |
| Profit growth | 270.3 | 30.9 | 21 of 158 | 87% |
| Market cap | 13 | 806 | 173 of 181 | 4% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 7 Oct 2026 · Compliance certificates filed for quarter ended Sept 30, 2026 | compliance | minimal | — | — |
| 7 Oct 2026 · Beryl Drugs files non applicability certificate under Reg 57(5) for Sep 2026 quarter | compliance | minimal | — | — |
| 30 Sept 2026 · Trading window closed ahead of Q2 FY2027 results | compliance | minimal | — | — |
| 30 Sept 2026 · 33rd AGM Voting Results: All 3 Resolutions Passed | board shareholder meetings | medium | — | — |
| 29 Sept 2026 · PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING | board shareholder meetings | medium | — | — |
| 29 Sept 2026 · Beryl Drugs raises related party transaction cap with Aminova to Rs 8 crore | strategic transactions | medium | — | — |
| 29 Sept 2026 · Outcome of 33rd Annual General Meeting | results | medium | — | — |
| 6 Sept 2026 · Beryl Drugs 33rd AGM on Sep 29, 2026; book closure Sep 23-29 | compliance | minimal | — | — |
| 3 Sept 2026 · Annual Report FY2025-26 filed; 33rd AGM on September 29, 2026 | investor communications | medium | — | — |
| 3 Sept 2026 · Beryl Drugs 33rd AGM on Sep 29; Aminova RPT limit raised to Rs 8 cr | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.